Citigroup
FBRX icon

Citigroup’s Forte Biosciences FBRX Stock Holding History

Citigroup’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,279
Closed -$34.9K – 6087
2025
Q4 		$34.9K Buy
+1,279
New +$22.4K ﹤0.01% 4698
2022
Q3 		– Sell
-5
Closed – – 5976
2022
Q2 		$0 Sell
5
-20
-80% -$635 ﹤0.01% 6353
2022
Q1 		$1K Sell
25
-76
-75% -$2.88K ﹤0.01% 6161
2021
Q4 		$5K Buy
101
+48
+91% +$3.23K ﹤0.01% 5657
2021
Q3 		$4K Buy
53
+28
+112% +$15.5K ﹤0.01% 5607
2021
Q2 		$21K Sell
25
-262
-91% -$236K ﹤0.01% 5269
2021
Q1 		$246K Hold
287
– – ﹤0.01% 3909
2020
Q4 		$261K Buy
287
+282
+5,640% +$265K ﹤0.01% 4780
2020
Q3 		$6K Sell
5
-2
-29% -$1.33K ﹤0.01% 6893
2020
Q2 		$2K Sell
7
-13
-65% -$5.81K ﹤0.01% 7404
2020
Q1 		$9K Buy
20
+4
+25% +$1.56K ﹤0.01% 7075
2019
Q4 		$3K Sell
16
-8
-33% -$1.81K ﹤0.01% 7492
2019
Q3 		$6K Sell
24
-13
-35% -$19.7K ﹤0.01% 7269
2019
Q2 		$92K Sell
37
-5
-12% -$14.8K ﹤0.01% 5951
2019
Q1 		$172K Sell
42
-1,177
-97% -$4.55M ﹤0.01% 5246
2018
Q4 		$3.75M Buy
1,219
+1,159
+1,932% +$4.99M ﹤0.01% 2087
2018
Q3 		$354K Buy
+60
New +$228K ﹤0.01% 4671
2018
Q2 		– Sell
-6
Closed -$28K – 7636
2018
Q1 		$28K Sell
6
-1
-14% -$4.63K ﹤0.01% 6546
2017
Q4 		$26K Buy
+7
New +$27.9K ﹤0.01% 6589
2017
Q3 		– Hold
0
– -$1K – 7294
2017
Q2 		– Hold
0
– – – 7141

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Citigroup's FBRX Position: Q1 2026 in Review

Citigroup sold out of Forte Biosciences (FBRX) in Q1 2026, closing a stake of 1,279 shares — an estimated $34.9K sold.

Citigroup first reported a position in FBRX in Q4 2017 and held it in 19 quarters. The position peaked at $3.75M in Q4 2018. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Citigroup reported no remaining Forte Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1,279 Forte Biosciences shares in Q1 2026, an estimated $34.9K.
  • Citigroup first reported a position in Forte Biosciences in Q4 2017 and held it in 19 quarters.
  • Citigroup's Forte Biosciences position peaked at $3.75M in Q4 2018.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.